Hydrogen Gas Therapy Slows ALS Progression and Extends Lifespan in Mice
Mutant superoxide dismutase 1-catalyzed hydrogen therapy for amyotrophic lateral sclerosis achieved by intercepting oxidative stress-neuroinflammation crosstalk
Research hubs: Brain & Nervous System · Musculoskeletal System
This research was done in animals. Results in animals often don't carry over to people.
- Evidence type
- Animal study (mouse)
- Authors
- Yihui Sun, Yingshuai Wang, Qianbo He, Min Zhao, Jiaru Guo, Chunjie Xu, Qiupeng Yan, Yanchun Chen, Bingqiang Zhang, Hongmei Du, Jing Huo, Yong Zhang, Haoyun Zhang, Yingjun Guan, Qianjun He
- Journal
- Acta Biomaterialia
- Year
- 2026
- PMID
- 42398690
- Study Type
- Mouse
- Delivery
- Gas (Sustained Release)
- Dose
- Oral Mg2Si nanosheets for sustained H2 release
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 0 (OpenAlex, as of November 2026)
- Country
- China
TL;DR
Sustained hydrogen release from oral Mg₂Si nanosheets slowed disease progression and extended survival in an ALS mouse model.
Key Finding
Oral magnesium-silicon nanosheets that slowly release hydrogen gas delayed ALS progression, improved motor function, and extended lifespan in transgenic mice with the disease.
Summary
Researchers tested a new form of hydrogen therapy in mice with a genetic form of ALS (a disease that damages nerve cells controlling movement). They created special magnesium-silicon particles that release hydrogen gas slowly in the digestive system. In genetically engineered mice with ALS, this treatment slowed disease progression, improved movement, and extended lifespan by reducing harmful molecules called free radicals and calming excessive immune activity in the nervous system.
Practical Takeaway
This is early-stage research in mice only, not humans. While the results are promising for understanding how sustained hydrogen delivery might help ALS, it's far too soon to know if this approach would work in people or be safe for human use. Much more research, including human clinical trials, would be needed before any conclusions could be drawn about practical applications.
Abstract (excerpt)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron degeneration in the brain and spinal cord, with mutant superoxide dismutase 1 (SOD1) induced oxidative stress and neuroinflammation as key pathogenic drivers. Here, we uncover that…